Abstract

The multiplexed, point-of-care measurement of specific antibodies could improve the speed with which diseases are diagnosed and their treatment initiated. To this end, we are developing E-DNA scaffold sensors, which consist of a rigid, nucleic acid “scaffold” attached on one end to an electrode and presenting both a redox reporter and an epitope on the other. In the absence of antibody, the reporter efficiently transfers electrons when interrogated electrochemically. Binding-induced steric hindrance limits movement, reducing electron transfer in a manner that is both easily measured and quantitatively related to target concentration. Previously we have used monoclonal antibodies to explore the analytical performance of E-DNA sensors, showing that they support the rapid, single-step, quantitative detection of multiple antibodies in small volume samples. Here, in contrast, we employ authentic human samples to better explore the platform’s clinical potential. Specifically, we developed E-DNA sensors targeting three HIV-specific antibodies and then compared the analytical and clinical performance of these against those of gold standard serological techniques. Doing so we find that, although the multistep amplification of an ELISA leads to a lower detection limits, the clinical sensitivity of ELISAs, E-DNA sensors and lateral-flow dipsticks are indistinguishable across our test set. It thus appears that, by merging the quantitation and multiplexing of ELISAs with the convenience and speed of dipsticks, E-DNA scaffold sensors could significantly improve on current serological practice.

Highlights

  • Antibodies are perhaps the broadest and most important class of diagnostic biomarkers, our ability to measure them at the point of care remains limited[1,2]

  • The platform consists of a gold electrode modified with a DNA strand that presents a redox reporter on its 3′-end, which generates an electrochemical signal, and a thiol group on its 5′-end, which anchors the DNA to the gold surface (Fig. 1)

  • Using these to test a commercially available enzymelinked immunosorbent assay (ELISA) (HIV1/2 Ab ELISA Kit) and a commercially available lateral flow immunoassay (UniGoldTM Recombigen® HIV-1/2), we found that both achieved 90% sensitivity and 100% specificity (Fig. 2)

Read more

Summary

Introduction

Antibodies are perhaps the broadest and most important class of diagnostic biomarkers, our ability to measure (as opposed to detect the presence of) them at the point of care remains limited[1,2]. Here we have expanded the platform to the detection of several antibodies diagnostic for HIV, and used a test set of HIV-positive and -negative human sera to characterize the new sensors’ clinical sensitivity and specificity relative to those of commercial ELISA and lateral flow immunoassays.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call